25B-NBOMe, a novel N-2-methoxybenzyl-phenethylamine (NBOMe) derivative, may induce rewarding and reinforcing effects via a dopaminergic mechanism: Evidence of abuse potential
Addiction Biology November 1, 2020 DOI: 10.1111/adb.12850 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Animal study Peer reviewed |
|---|---|
| Population | Rats |
| Interventions | 25B-NBOMe SCH23390 Haloperidol Ketanserin |
| Key points | 25B-NBOMe induces rewarding and reinforcing effects via a dopaminergic mechanism, suggesting abuse potential. |
Abstract
Abstract An increasing number of N ‐2‐methoxybenzyl‐phenethylamine (NBOMe) derivatives are being misused worldwide, including the potent hallucinogen 2‐(4‐bromo‐2,5‐dimethoxyphenyl)‐ N ‐(2‐methoxybenzyl)ethanamine (25B‐NBOMe). However, the number of studies characterizing the abuse potential and psychopharmacological properties of 25B‐NBOMe is limited; thus, we examined its rewarding and reinforcing effects using conditioned place preference (CPP) and self‐administration (SA) tests. Pretreatment with SCH23390 (SCH), Haloperidol (HAL), and ketanserin (KS), antagonists of dopamine D1 (DRD 1 ), dopamine D2 (DRD 2 ), and serotonin 2A (5‐HT 2A receptor) receptors, respectively, was utilized during a CPP test to investigate the involvement of the dopaminergic and serotonergic systems in 25B‐NBOMe‐mediated effects. We also examined the effects of 25B‐NBOMe on the expression of dopamine‐related proteins in the nucleus accumbens (NAcc) and ventral tegmental area (VTA). Then, we measured the dopamine level, phosphorylated CREB (p‐CREB), deltaFosB (ΔFosB), and brain‐derived neurotrophic factor (BDNF) in the NAcc. In addition, we explored the involvement of 5‐HT 2A receptors in the 25B‐NBOMe‐induced head twitch response (HTR). We also examined the effects of 25B‐NBOMe on brain wave activity using electroencephalography. 25B‐NBOMe elicited CPP and SA. SCH and HAL blocked 25B‐NBOMe‐induced CPP, whereas KS did not. Moreover, 25B‐NBOMe altered the DRD 1 , DRD 2 , and dopamine transporter expression and increased dopamine levels. It also induced changes in p‐CREB, ΔFosB, and BDNF expression. 25B‐NBOMe induced HTR and increased 5‐HT 2A receptor mRNA levels, effects inhibited by KS. Furthermore, 25B‐NBOMe altered delta and gamma wave activity, which was normalized by SCH and HAL. These findings show that 25B‐NBOMe may induce rewarding and reinforcing effects via a dopaminergic mechanism, suggesting its abuse potential.
Citations in the library
Cited by 21
- Designer drugs: mechanism of action and adverse effects Archives of Toxicology April 1, 2020
- NBOMes–Highly Potent and Toxic Alternatives of LSD Frontiers in Neuroscience February 26, 2020
- Molecular and clinical aspects of potential neurotoxicity induced by new psychoactive stimulants and psychedelics Experimental Neurology June 4, 2021
- Neurochemical and Behavioral Effects of a New Hallucinogenic Compound 25B-NBOMe in Rats Neurotoxicity Research December 18, 2020
- Tolerance to neurochemical and behavioral effects of the hallucinogen 25I-NBOMe Psychopharmacology May 25, 2021
and 16 more in the library
Cites 9
- Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology December 1, 2015
- Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice Journal of Psychopharmacology December 8, 2010
- Two cases of severe intoxication associated with analytically confirmed use of the novel psychoactive substances 25B-NBOMe and 25C-NBOMe Clinical Toxicology 2014
- Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function. Psychopharmacology March 1, 2014
- Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats. Psychopharmacology 2013
and 4 more in the library